Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $8
Cantor Fitzgerald analyst Charles Duncan maintains Vaxart (NASDAQ:VXRT) with a Overweight and lowers the price target from $11 to $8.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
Vaxart Shares Positive Top-line Data From Mid-Stage Oral Pill COVID-19 Vaccine Study
Vaxart (NASDAQ: VXRT) announced positive top-line data from the first part of a planned two-part Phase 2 study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S.
The top-line data readout exhibited that the trial met its primary safety and secondary immunogenicity endpoints.
Why Nutanix Is Trading Higher By 16%; Here Are 33 Stocks Moving Premarket
Gainers
Bright Green Corporation (NASDAQ: BGXX) shares rose 63.8% to $2.26 in pre-market trading after gaining around 33% on Wednesday.
